| Breast cancer in China L Fan, K Strasser-Weippl, JJ Li, J St Louis, DM Finkelstein, KD Yu, ... The lancet oncology 15 (7), e279-e289, 2014 | 1712 | 2014 |
| Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies YZ Jiang, D Ma, C Suo, J Shi, M Xue, X Hu, Y Xiao, KD Yu, YR Liu, Y Yu, ... Cancer cell 35 (3), 428-440. e5, 2019 | 686 | 2019 |
| Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer Y Xiao, D Ma, S Zhao, C Suo, J Shi, MZ Xue, M Ruan, H Wang, J Zhao, ... Clinical cancer research 25 (16), 5002-5014, 2019 | 280 | 2019 |
| Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China L Fan, Y Zheng, KD Yu, GY Liu, J Wu, JS Lu, KW Shen, ZZ Shen, ... Breast cancer research and treatment 117, 409-416, 2009 | 235 | 2009 |
| Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer YR Liu, YZ Jiang, XE Xu, KD Yu, X Jin, X Hu, WJ Zuo, S Hao, J Wu, ... Breast Cancer Research 18, 1-10, 2016 | 216 | 2016 |
| Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer KD Yu, R Zhu, M Zhan, AA Rodriguez, W Yang, S Wong, A Makris, ... Clinical cancer research 19 (10), 2723-2733, 2013 | 194 | 2013 |
| Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value YZ Jiang, YR Liu, XE Xu, X Jin, X Hu, KD Yu, ZM Shao Cancer research 76 (8), 2105-2114, 2016 | 183 | 2016 |
| Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial KD Yu, FG Ye, M He, L Fan, D Ma, M Mo, J Wu, GY Liu, GH Di, XH Zeng, ... JAMA oncology 6 (9), 1390-1396, 2020 | 159 | 2020 |
| The prognostic and predictive potential of Ki-67 in triple-negative breast cancer X Zhu, L Chen, B Huang, Y Wang, L Ji, J Wu, G Di, G Liu, K Yu, Z Shao, ... Scientific reports 10 (1), 225, 2020 | 131 | 2020 |
| Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling B Dave, S Granados-Principal, R Zhu, S Benz, S Rabizadeh, ... Proceedings of the National Academy of Sciences 111 (24), 8838-8843, 2014 | 119 | 2014 |
| The spectrum of BRCA mutations and characteristics of BRCA‐associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next‐generation sequencing GT Lang, JX Shi, X Hu, CH Zhang, L Shan, CG Song, ZG Zhuang, AY Cao, ... International journal of cancer 141 (1), 129-142, 2017 | 114 | 2017 |
| Development and trends of surgical modalities for breast cancer in China: a review of 16-year data KD Yu, GH Di, J Wu, JS Lu, KW Shen, ZZ Shen, ZM Shao Annals of surgical oncology 14, 2502-2509, 2007 | 109 | 2007 |
| Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis KD Yu, S Huang, JX Zhang, GY Liu, ZM Shao BMC cancer 13, 1-10, 2013 | 104 | 2013 |
| Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component KD Yu, LM Wu, GY Liu, J Wu, GH Di, ZZ Shen, ZM Shao Annals of surgical oncology 18, 1342-1348, 2011 | 100 | 2011 |
| The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation X Jin, XE Xu, YZ Jiang, YR Liu, W Sun, YJ Guo, YX Ren, WJ Zuo, X Hu, ... Science advances 5 (3), eaat9820, 2019 | 97 | 2019 |
| Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy KD Yu, J Wu, ZZ Shen, ZM Shao The Journal of Clinical Endocrinology & Metabolism 97 (12), E2201-E2209, 2012 | 90 | 2012 |
| Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III trial J Li, K Yu, D Pang, C Wang, J Jiang, S Yang, Y Liu, P Fu, Y Sheng, ... Journal of Clinical Oncology 38 (16), 1774, 2020 | 89 | 2020 |
| Comprehensive transcriptome profiling reveals multigene signatures in triple-negative breast cancer YR Liu, YZ Jiang, XE Xu, X Hu, KD Yu, ZM Shao Clinical cancer research 22 (7), 1653-1662, 2016 | 85 | 2016 |
| The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy S Chen, YZ Jiang, L Huang, RJ Zhou, KD Yu, Y Liu, ZM Shao Clinical cancer research 19 (24), 6853-6862, 2013 | 82 | 2013 |
| GATA3 mutations define a unique subtype of luminal‐like breast cancer with improved survival YZ Jiang, KD Yu, WJ Zuo, WT Peng, ZM Shao Cancer 120 (9), 1329-1337, 2014 | 81 | 2014 |
